Tag Archives: medical technology

Pressemitteilungen

SpiderSoM öffnet breiten Zugang zu FPGA-Technologie

ARIES Embedded ergänzt industrielles MX10-SoM um Einstiegs-System-on-Module für erweiterten Anwenderkreis

ARIES Embedded, Spezialist für Embedded-Services und -Produkte, stellt mit dem FPGA-basierten System-on-Module (SoM) „SpiderSoM“ ein Basismodul für den Einstieg in die FPGA-Programmierung vor. Wie auch sein Industrie-Upgrade MX10 ist das SpiderSoM ein programmierbares, flexibles Board auf Basis des Intel® MAX®10 FPGAs. „Mit dem SpiderSoM senken wir bewusst die Einstiegsschwelle und öffnen die Designarbeit mit FPGAs für alle Entwicklergruppen“, erläutert Andreas Widder, Geschäftsführer von ARIES Embedded. „Damit erreichen wir Anwenderkreise auch außerhalb industrieller Aufgaben und vergrößern die Community für den fachlichen Austausch rund um die leistungsstarke FPGA-Technologie.“ Das Einsteiger-SoM bietet vollständige FPGA-Funktionalität wie unter anderem die Unterstützung für verschiedene Softcore-CPUs.

Prompter Projektstart und offenes Designkonzept

Für den schnellen Designstart mit sowohl SpiderSoM als auch MX10-SoM stellt ARIES Embedded das Evaluationsboard SpiderBase zur Verfügung. Die kostengünstige und ausgesprochen flexible Plattform erlaubt Anwendern, in sehr kurzer Zeit ein laufendes System entsprechend der benötigten Spezifikationen aufzusetzen. Das Board enthält ein großes Experimentierfeld. Mit dem SpiderBoard unterstützt ARIES Embedded ein freies und offenes Designkonzept: Alle Ressourcen wie etwa Design- und Gerberdateien sowie der Source Code sind unter Open-Source-Lizenzen erhältlich, KiCAD-Designdaten unter CERN OHL v1.2.

Einstieg ins FPGA-Programmieren

Das SpiderSoM unterstützt Intel MAX®10-FPGAs von 10M02SC bis 10M16SA im U169-Gehäuse mit Einzelspannungsversorgung. Das Board mit 70 auf 35 mm bietet GPIO-Pins und optional 4 MBit SPI NOR-Flash, 8 MBit SDRAM sowie RTC mit Backup-Batterie und Lithium-Ionen- (Li-Ion) oder Lithium-Polymer-Akkus (Li-Po).

Das Wiki auf spiderboard.org hilft bei ersten Schritten mit der neuen Plattform, dafür stehen Schritt-für-Schritt-Anleitungen wie „Getting Started“ oder ein Beispiel für die Implementierung einer RISC-V Softcore-CPU zur Verfügung.

MX10 SoM für den industriellen Einsatz

Für professionelle Elektronikdesigns in Industrieanwendungen stellt ARIES Embedded das MX10-SoM für Intel MAX®10-FPGAs von 10M04DC bis 10M50DA im F256-Gehäuse bereit. Das SoM verfügt im Vergleich zum SpiderSoM zusätzlich über 128/256/512 MBit DDR3 DRAM (für 10M 16/25/40/50 FPGAs), einen programmierbaren Taktgenerator und PLL mit optionalem, externen Referenzeingang. Die 178 FPGA GPIO-Pins beinhalten 13 LVDS-Sender und 54 -Empfänger. Über die programmierbaren, hocheffizienten Powermanagement-ICs (PMIC) lassen sich die Ein- und Ausgangsspannungen des FPGAs konfigurieren.

Über ARIES Embedded
ARIES Embedded bietet kundenspezifische Hardware- und Software-Entwicklung und Standardprodukte für Industrie und Landwirtschaft. Der Schwerpunkt des 2001 gegründeten Embedded-Spezialisten mit Sitz in Fürstenfeldbruck, Deutschland, liegt auf der FPGA-Technologie und Open-Source-Software. Das Angebot umfasst modulare Systeme für den flexiblen und schnellen Einsatz in funktionalen Prototypen, Pilotserien und der Serienproduktion. Im Kundenauftrag passt ARIES Embedded Standardprojekte individuell an Projektanforderungen an.

Firmenkontakt
ARIES Embedded GmbH
Andreas Widder
Schöngeisinger Straße 84
82256 Fürstenfeldbruck
+49 8141 36 367 0
ma@ahlendorf-communication.com
http://www.aries-embedded.com

Pressekontakt
ahlendorf communication
Mandy Ahlendorf
Hermann-Roth-Straße 1
82065 Baierbrunn
+49 89 41109402
ma@ahlendorf-communication.com
http://www.ahlendorf-communication.com

Die Bildrechte liegen bei dem Verfasser der Mitteilung.

Pressemitteilungen

SpiderSoM Opens Broad Access to FPGA Technology

ARIES Embedded Complements Industrial MX10-SoM by Entry-Level System-on-Module for Expanded User Community

With the FPGA-based System-on-Module (SoM) „SpiderSoM“, ARIES Embedded, specialist for embedded services and products, presents a basic module for getting started with FPGA programming. Similar to its industrial upgrade MX10, the SpiderSoM is a programmable, non-volatile board based on the Intel® MAX®10 FPGAs. „With the SpiderSoM, we are consciously lowering the entry threshold, opening design work with FPGAs to all development groups,“ explained Andreas Widder, Managing Director of ARIES Embedded. „This enables us to reach out to users outside of industrial tasks and to expand the community for the professional information exchange on high-performance FPGA technology. The entry-level SoM offers complete FPGA functionality, including support for various softcore CPUs.

Prompt Project Start and Open Design Concept

ARIES Embedded provides the evaluation board SpiderBase for a fast design start with both SpiderSoM and MX10-SoM. The cost-effective and extremely flexible platform allows users to set up a running system according to the required specifications in a very short time. The board contains a large prototype area. With the SpiderBoard, ARIES Embedded supports the free and open design concept: All resources such as design and Gerber files as well as the source code are available under open source licenses, KiCAD design data under CERN OHL v1.2.

Introduction to FPGA Programming

The SpiderSoM supports Intel MAX®10 FPGAs from 10M02SC to 10M16SA in U169 package with single power supply. The board, with dimensions of 70 by 35 mm, offers GPIO pins and optional 4 Mbit SPI NOR flash, 8 Mbit SDRAM and RTC with battery backup and lithium ion (Li-Ion) or lithium polymer (Li-Po) charger.

The Wiki on spiderboard.org helps users through the first steps with the new platform. Step-by-step instructions like ‚Getting Started‘ or an example for the implementation of a RISC-V softcore CPU are available.

MX10-SoM for Industrial Use

For professional electronics designs in industrial applications, ARIES Embedded offers the MX10-SoM for Intel MAX®10-FPGAs from 10M04DC to 10M50DA in the F256 package. To compare to the SpiderSoM, the MX10-SoM also features 128/256/512 Mbit DDR3 DRAM (for 10M 16/25/40/50 FPGAs), a programmable clock generator and PLL with optional external reference input. The 178 FPGA GPIO pins include 13 LVDS transmitters and 54 receivers. The FPGA’s input and output voltages can be configured via programmable, high-efficient power management ICs (PMICs).

About ARIES Embedded
ARIES Embedded provides hardware and software development and standard products for industrial and agricultural sectors. The 2001 founded embedded specialist headquartered in Fuerstenfeldbruck, Germany, focuses on FPGA technology and open source software. The portfolio comprises of modular systems for flexible and fast use in functional prototypes, pilot series and mass production. On customer request, ARIES Embedded individually customizes standard products in accordance with project requirements.

Company-Contact
ARIES Embedded GmbH
Andreas Widder
Schöngeisinger Straße 84
82256 Fürstenfeldbruck
Phone: +49 8141 36 367 0
E-Mail: ma@ahlendorf-communication.com
Url: http://www.aries-embedded.com

Press
ahlendorf communication
Mandy Ahlendorf
Hermann-Roth-Straße 1
82065 Baierbrunn
Phone: +49 89 41109402
E-Mail: ma@ahlendorf-communication.com
Url: http://www.ahlendorf-communication.com

Die Bildrechte liegen bei dem Verfasser der Mitteilung.

Pressemitteilungen

Embedded World: ARIES Embedded Will Present New System-on-Module with PolarFire FPGA

M100PF Board Enhances and Optimizes Microchip’s PolarFire FPGA for Industrial and Medical Technology

ARIES Embedded, specialist for embedded services and products, will display the new M100PF System-on-Module (SoM) based on Microchip’s PolarFire FPGA (Field Programmable Gate Array) family at Embedded World from February 26 to 28, 2019 in Nuremburg, Germany. At stand 441 in hall 3A, the embedded specialist will also introduce the complementary evaluation platform M100PFEVP, which delivers a fast and easy project start for customers. „Our new M100PF board provides the full flexibility of the popular FPGAs for demanding applications in industrial and medical technology,“ stated Andreas Widder, Managing Director of ARIES Embedded. „PolarFire captivates with up to 50 percent lower power consumption than competing FPGAs, at mid-range densities with exceptional safety and reliability.“ With the SoM, ARIES Embedded extends the FPGA functionality with RAM, Flash, Clocking and additional features.

M100PF Flexibly and Reliably Serves Industrial Applications

For industrial use, the system-on-module allows an expanded temperature range, from 0° to +70°C up to -40° to +85°C. On the ARIES SoM, the PolarFire FPGAs provide 100k, 192k, or 300k logic elements (LE) and feature 12.7G transceivers with up to 50 percent lower power consumption. The 256 Mbit configuration storage, the DDR3 RAM (512 Mbit, 1 or 2 Gbit), as well as 4 to 64 Gbit eMMC NAND Flash allow the development of complex high performance designs. Further features of the 72 by 40 mm small SoMs are: 8 SerDes with 250 Mbps to 12.5 Gbps, 2 PCI express Gen2 end points/root port slots, rich user I/O, and 2 Samtec QSH-090-01-F-D-A board-to-board connectors.

Easy Project Start with Evaluation Board M100PFEVP

ARIES Embedded provides the corresponding evaluation platform M100PFEVP for a smooth and fast project start. It enables customers to evaluate the PolarFire FPGA, realize prototypes and even use the FPGA in series production. The evaluation board contains 2 gigabit Ethernet, USB, and 4 DSub9 interfaces for CAN, RS232, and others, in addition to Pmod and HSMC extension connectors and a microSD card slot. The M100PFEVP starter kit includes the M100PVEVP baseboard, M100PF-1DB storage extensions, a 7-inch touchscreen, and power supply.

About ARIES Embedded
ARIES Embedded provides hardware and software development and standard products for industrial and agricultural sectors. The 2001 founded embedded specialist headquartered in Fuerstenfeldbruck, Germany, focuses on FPGA technology and open source software. The portfolio comprises of modular systems for flexible and fast use in functional prototypes, pilot series and mass production. On customer request, ARIES Embedded individually customizes standard products in accordance with project requirements.

Company-Contact
ARIES Embedded GmbH
Andreas Widder
Schöngeisinger Straße 84
82256 Fürstenfeldbruck
Phone: +49 8141 36 367 0
E-Mail: ma@ahlendorf-communication.com
Url: http://www.aries-embedded.com

Press
ahlendorf communication
Mandy Ahlendorf
Hermann-Roth-Straße 1
82065 Baierbrunn
Phone: +49 89 41109402
E-Mail: ma@ahlendorf-communication.com
Url: http://www.ahlendorf-communication.com

Die Bildrechte liegen bei dem Verfasser der Mitteilung.

Pressemitteilungen

Embedded World: ARIES Embedded präsentiert neues System-on-Module mit PolarFire FPGA

M100PF-Board erweitert und optimiert Microchips PolarFire FPGA für Industrie und Medizintechnik

ARIES Embedded, Spezialist für Embedded-Services und -Produkte, präsentiert auf der Embedded World vom 26. bis 28. Februar 2019 in Nürnberg das neue System-on-Module (SoM) M100PF auf Basis der PolarFire FPGA-Familie (Field Programmable Gate Array) von Microchip. Am Stand 441 in Halle 3A stellt der Embedded-Spezialist zudem die ergänzende Evaluierungsplattform M100PFEVP vor, die Kunden einen schnellen und einfachen Projektstart ermöglicht. „Unser neues M100PF-Board bietet die volle Flexibilität der beliebten FPGAs für anspruchsvolle Anwendungen in Industrie und Medizintechnik“, erläutert Andreas Widder, Geschäftsführer von ARIES Embedded. „Der PolarFire besticht durch bis zu 50 Prozent niedrigere Leistungsaufnahme als andere FPGAs, und das bei mittlerer Dichte und außerordentlicher Sicherheit und Zuverlässigkeit.“ Mit dem SoM erweitert ARIES Embedded die FPGA-Funktionalität um RAM, Flash, Clocking und weitere Features.

M100PF bedient Industrieanwendungen flexibel und zuverlässig

Für den industriellen Einsatz erlaubt das System-on-Module einen von 0° bis +70°C auf -40° bis +85°C erweiterten Temperaturbereich. Die PolarFire-FPGAs auf dem ARIES SoM bieten 100k, 192k oder 300k Logikelemente (LE) und einen 12,7G-Transceiver bei bis 50 Prozent geringerem Stromverbrauch. Der Konfigurationsspeicher mit 256 MBit und das DDR3 RAM mit 512 MBit, 1 oder 2 GBit sowie 4 bis 64 GBit eMMC NAND Flash ermöglichen die Entwicklung komplexer Hochleistungsdesigns. Weitere Features des nur 72 auf 40 mm großen SoMs sind: 8 SerDes mit 250 MBit/s bis12,5 GBit/s, 2 PCI-Express Gen2 Endpunkt/Rootport-Steckplätze, Rich-User In-/Output und 2 Samtec QSH-090-01-F-D-A Board-to-Board-Steckverbinder.

Einfacher Projektstart mit Evaluierungsboard M100PFEVP

Für einen reibungslosen und schnellen Projektstart stellt ARIES Embedded die entsprechende Evaluierungsplattform M100PFEVP bereit. Damit können die Kunden das PolarFire FPGA evaluieren, Prototypen realisieren und den FPGA sogar in Serie verwenden. Das Evaluierungsboard enthält 2 Gigabit-Ethernet-, USB- sowie 4 DSub9-Schnittstellen für CAN, RS232, etc., außerdem Pmod-und HSMC-Erweiterungsstecker und einen microSD-Kartensteckplatz. Das Starterpaket M100PFEVP-Kit umfasst das M100PFEVP-Baseboard, M100PF-1DB Speichererweiterungen, einen 7-Zoll-Touchscreen und ein Netzteil.

Über ARIES Embedded
ARIES Embedded bietet kundenspezifische Hardware- und Software-Entwicklung und Standardprodukte für Industrie und Landwirtschaft. Der Schwerpunkt des 2001 gegründeten Embedded-Spezialisten mit Sitz in Fürstenfeldbruck, Deutschland, liegt auf der FPGA-Technologie und Open-Source-Software. Das Angebot umfasst modulare Systeme für den flexiblen und schnellen Einsatz in funktionalen Prototypen, Pilotserien und der Serienproduktion. Im Kundenauftrag passt ARIES Embedded Standardprojekte individuell an Projektanforderungen an.

Firmenkontakt
ARIES Embedded GmbH
Andreas Widder
Schöngeisinger Straße 84
82256 Fürstenfeldbruck
+49 8141 36 367 0
ma@ahlendorf-communication.com
http://www.aries-embedded.com

Pressekontakt
ahlendorf communication
Mandy Ahlendorf
Hermann-Roth-Straße 1
82065 Baierbrunn
+49 89 41109402
ma@ahlendorf-communication.com
http://www.ahlendorf-communication.com

Die Bildrechte liegen bei dem Verfasser der Mitteilung.

Pressemitteilungen

TAITRA Presents Top Products at MEDICA 2018

TAITRA Presents Top Products at MEDICA 2018

The Taiwan External Trade Development Council (TAITRA) promotes the sale of Taiwanese products at home and abroad. At today’s MEDICA press conference, TAITRA focused on particularly innovative products from the fields of medical technology and e-health.

Düsseldorf, 13 November 2018
Five Taiwanese exhibitors took the opportunity to present their latest product innovations to international trade journalists. At the invitation of TAITRA, representatives from HTC, Taiwan Main Orthopedics, AmCad BioMed, BAUI Biotech and Rehabotics Medical Technology stood before an engaged audience and presented insights into the ambitious research and development work in Taiwan as well as their latest product innovations.

For example, the HTC Group relies heavily on virtual reality and impresses in two respects with the VR glasses VIVE. First, VIVE provides access to the first anatomical 3D atlas. On the other hand, the glasses have already achieved initial successes in the therapy of the fear of heights. Absolutely innovative is the fact that the therapy is accompanied by a virtual trainer instead of a human therapist.

The Virtual Dissection Table and the surgical glasses from Taiwan Main Orthopedics are also highly technical. The treatment table, which displays fully anatomical structures and, is suitable both for teaching purposes and for planning surgical interventions. The intelligent surgical spectacles complement the range and enable doctors to partially look into the patient’s body during a minimally invasive procedure and to display a 3D model of nerves and vessels.

AmCad BioMed Corporation is countering obstructive sleep apnea syndrome with a promising new diagnostic device. The AmCAD-UO consists of a positioning system and computer-aided recognition software. After only ten minutes, the AmCAD-UO provides accurate results and thus ensures efficiency and flexibility in treatment.

After two years of research and development, BAUI Biotech launches the NOVA Minimally Invasive System, which can be used to optimize surgical procedures on the spine. Both the patient and the surgeon benefit from the versatile small screw. The NOVA system effectively stabilizes the spinal column using polyaxial screws with long, fragile blades.

Rehabotics Medical Technology Corporation presents an innovative robotics product. The Mirror Hand was developed to support and accelerate the rehabilitation of the hands, for example after strokes, and to provide patients with practical help in coping with their everyday lives. Weighing only 750 grams, it is by far one of the lightest robotic rehabilitation devices for the hand.

Taiwan relies on technological progress
For many years, Taiwan has enjoyed an excellent reputation as a location for the manufacture of high-quality consumer electronics and medical technology equipment, which the small country has now been able to develop into a significant competitive advantage. TAITRA is committed to those companies that are entering the market with particularly innovative ideas and acts as a partner, mediator and consultant when it comes to initiating and concluding transactions between Taiwanese companies and customers at home and abroad. At the TAITRA joint exhibition stand at the current MEDICA, 15 companies present their new products, which have received the „Taiwan Excellence Award“.

About TAITRA:
TAITRA was founded in 1970 as a non-profit trade promotion organization. Supported by the Taiwanese government, TAITRA opens up new national and international sales markets for member companies from various sectors. TAITRA has created the „Taiwan Excellence“ label, which is awarded every year to particularly innovative products or companies. TAITRA is headquartered in Taiwan’s capital Taipei. The organization has a total of 61 branches worldwide. In Germany, TAITRA has two offices in Düsseldorf and Munich.

Founded in 1970 to help promote foreign trade, the Taiwan External Trade Development Council (TAITRA) is the foremost non-profit trade promotion organization in Taiwan. Jointly sponsored by the government, industry associations, and several commercial organizations, TAITRA assists Taiwan businesses and manufacturers with reinforcing their international competitiveness and in coping with the challenges they face in foreign markets.

TAITRA boasts a well-coordinated trade promotion and information network of over 1,300 trained specialists stationed throughout its Taipei headquarters, four local branch offices in Hsinchu, Taichung, Tainan and Kaohsiung, and 60 overseas branch offices worldwide. Together with its sister organizations, Taiwan Trade Center (TTC) and Taipei World Trade Center (TWTC), TAITRA has created a wealth of trade opportunities through effective promotion strategies.

Company-Contact
Taiwan External Trade Development Council
Frances Lin
Immermannstr. 33
40210 Dusseldorf
Phone: +49 (0)228 / 919 37 -66
E-Mail: taiwanexcellence@agentur-drilling.de
Url: https://www.taiwanexcellence2018.de/pk/

Press
DRILLING GmbH
Ben Giese
CelsiusStr. 43
53125 Bonn
Phone: +49 (0)228 / 919 37 -66
E-Mail: taiwanexcellence@agentur-drilling.de
Url: https://www.taiwanexcellence2018.de/pc/

Pressemitteilungen

biolitec® Medica 2017

FiLaC® confirms success with long-term study – New therapy method for endometriosis – Mobile LEONARDO® Mini laser can also be used for varicose veins

biolitec® Medica 2017

LEONARDO® laser family by biolitec® (Source: @ biolitec®)

Jena, November 13, 2017 – The success of FiLaC® therapy for the particularly painless and sphincter-friendly removal of anal fistulas from biolitec®, the technology leader in minimally invasive laser therapy, has been confirmed by a recently published long-term study. Very good results in first-line therapy (64.1%) and even better second-line treatment cure rates (85.5%). The study was carried out between October 2009 and July 2014 at the rectum and pelvic floor centre in Cologne (EBZ) by Dr. A. Wilhelm and other researchers on 117 patients.

With ELLA, the new treatment method for endometriosis, biolitec® is expanding its range of therapies in the field of gynaecology. The low-maintenance LEONARDO® DUAL 45 diode laser with its thin, high-quality flexible glass fibers and narrow laparoscopic tubes enables precise control of the laser beam. Initial results of a study confirm the rapid recovery of the AMH value and the significant maintenance of the ovarian reserve.

The biolitec® team will be presenting the whole range of the proven LEONARDO® laser family at booth H46 in hall 10.
The LEONARDO® laser family includes the LEONARDO® Dual series lasers in the 45 Watt, 100 Watt and 200 Watt power ranges, which are all characterized by the continuous use of the two wavelengths 980nm and 1470nm during the treatment. These lasers are the most versatile medical lasers available on the market today. They are suitable for phlebology and proctology as well as minimally invasive procedures in urology, gynaecology, orthopaedics, thoracic surgery and pneumology.

The innovative LEONARDO® Mini has also been part of the family for a year. Weighing only 900 grams this device is available in a version with a wavelength of 1470nm and as LEONARDO® Mini Dual with the two wavelengths 980nm and 1470nm. The small laser can also be used mobile in the established treatment methods of biolitec® for venous diseases, haemorrhoids, fistulas, a broad range of ENT disorders and gynaecological diseases. In addition, the new LEONARDO® Mini can carry out the proven ELVeS® Radial® 2ring laser therapy for the treatment of varicose veins. Sports injuries, inflammations and overloads can be treated quickly, precisely and non-invasively with the 15 Watt LEONARDO® Mini Athletic, which is available in the combinable wavelengths 810nm and 980nm.

The proven, unique XCAVATOR® laser fiber for the treatment of benign prostatic hyperplasia (BPH) has been significantly improved by biolitec®. Thanks to the optimized absorption capacity in water and hemoglobin, the new XCAVATOR® fiber enables the surgeon to work even faster and more precisely, so that the minimally invasive LIFE procedure of biolitec® can reduce side effects and pain even better than before.

biolitec® also opened its own branch office in Switzerland half a year ago, in order to be able to take into account the importance and high standards of the Swiss medical technology market. At www.biolitec.com, interested parties can find out more about the innovative laser therapies of biolitec®. From November 13 to 16 biolitec® will be represented at the Medica in Dusseldorf at booth H46 in hall 10.

About biolitec
biolitec® is one of the world“s leading medical technology companies in the field of laser applications and the only provider which possesses all the relevant core competences in the field of photodynamic therapy (PDT) – photosensitizers, lasers and fibre optic cables. Besides laser-supported treatment of cancers with the drug Foscan®, biolitec® researches and markets above all minimally invasive, gentle laser procedures.
ELVeS® Radial® (Endo Laser Vein System) is the world“s most-used laser system to treat venous insufficiency. The LEONARDO® diode laser from biolitec® is the first universally applicable medical laser which has a combination of two wavelengths, 980nm and 1470nm, and which can be used across disciplines. The innovative contact fibre XCAVATOR® in conjunction with the LEONARDO® DUAL 200 Watt laser allows in urology a gentle treatment of e.g. benign prostate enlargement (BPH). The light-weight LEONARDO® Mini laser weighing only 900 g was developed especially for mobile application on site. Gentle laser applications in the fields of proctology, ENT, gynecology, thorax surgery and pneumology are also part of biolitec®“s field of business. More information available at www.biolitec.com

Contact
biolitec biomedical technology GmbH
Joern Gleisner
Otto-Schott-Str. 15
07745 Jena
Phone: +49 (0) 3641 / 51953-36
Fax: +49 (0) 6172 / 27159-69
E-Mail: joern.gleisner@biolitec.com
Url: http://www.biolitec.com

Pressemitteilungen

Biologisation of medical technology – partner companies wanted

ZIM supports new „BioHyMed“ network project for developing biohybrid products

Biologisation of medical technology - partner companies wanted

The BioHyMed kick-off meeting participants (Source: BioRegio STERN/Anne Faden)

(Stuttgart) – The Central Innovation Programme for SMEs (ZIM) of the German Federal Ministry for Economic Affairs and Energy (BMWi) is now supporting the new „BioHyMed“ project as a ZIM cooperation network. For at least a year, BioRegio STERN Management GmbH will now receive a total of 116,000 euros to establish a network for developing biohybrid products and processes. Together with universities, clinics and scientific institutions in the region and six SMEs as project partners, this will drive forward the biologisation of medical technology. More companies are welcome to join the network as project partners. They will receive targeted support to enable them to also submit promising applications for research and development to ZIM if required.

The participants in the new BioHyMed network are engaged in research and development in one of the most ground-breaking fields of the health care industry – the biologisation of medical technology. The combination of biological and technical products or processes – called biohybrids – will in future be commonplace in operating theatres. These include implants that either replace damaged cells, tissue or organs or stimulate the healing process – regeneration rather than replacement. The real challenges for medical technology are also the new procedures for integrating biological processes, mechanical instruments and high-tech electronics. Another aim of the BioHyMed project is to develop new methods and materials for coating and „activating“ surfaces using biological components. Coatings using tailored biomolecules or the body’s own cells promise better healing and fewer rejection reactions.

In-vitro diagnostics is another area covered by the project. This includes innovative analysis systems to identify hospital germs quickly and reliably on site, for example, but also companion diagnostics and biomarker identification procedures i.e. genetic investigations for planning customised therapy. For Project Manager Dr. Verena Grimm from BioRegio STERN Management GmbH, patient benefits are the project“s top priority. „Linking biotechnology and medical technology opens up entirely new diagnostic and therapeutic approaches.“

The Verein zur Förderung der Biotechnologie und Medizintechnik e.V. was the original initiator of the project, and the successful application to ZIM was then submitted by BioRegio STERN Management GmbH. The Verein is an associated partner and will provide an advisory council to undertake expert assessments of funding applications from new project partners. TETEC GmbH, the NMI Natural and Medical Sciences Institute, Medical Valley Hechingen Akademie e.V. and the urology clinic and Institute of Medical Microbiology and Hygiene at Eberhard Karls University Tübingen are also associated partners.

The BioHyMed project will initially receive a total of 116,000 euros over one year from ZIM and will launch on April 1 with these six SMEs from BioRegio STERN:
-HB Technologies GmbH, Tübingen
-BioTeSys GmbH, Esslingen
-CeGaT GmbH, Tübingen
-Computomics GmbH, Tübingen
-Mediagnost GmbH, Reutlingen
-PolyMedics Innovations GmbH, Denkendorf.
However, more SMEs are welcome. „We offer interested companies the uncomplicated opportunity to also become project partners,“ explains Dr. Grimm. „A consortium of several partners can even submit project applications to ZIM with a value of up to two million euros.“

About BioRegio STERN Management GmbH:
BioRegio STERN Management GmbH is a skill-sharing network, providing a help and ad-vice centre for founders of new businesses, entrepreneurs and researchers in the life sciences sector in the cities of Stuttgart, Tübingen, Esslingen and Reutlingen and the Stuttgart and Neckar-Alb regions. BioRegio STERN Management GmbH represents the interests of these market players in dealings with political circles, the media and associations and provides advice on grant applications and corporate financing. Key focal points include regenerative medicine, medical technology and the automation of biotechnology. Managing Director Dr. Klaus Eichenberg is a molecular and cell biologist and investment analyst.

Firmenkontakt
BioRegio STERN Management GmbH
Klaus Eichenberg
Friedrichstrasse 10
70174 Stuttgart
+49 (0)711-870354-0
info@bioregio-stern.de
http://www.bioregio-stern.de/en

Pressekontakt
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70174 Stuttgart
+49 (0)711-6070719
info@zeeb.info
http://www.zeeb.info

Pressemitteilungen

Understand industries, connect industries

HR news BioRegio STERN Management GmbH – Biotechnologist Dr. Verena Grimm is new project manager

Understand industries, connect industries

Dr. Verena Grimm, project manager BioRegio STERN Management GmbH (Source: private)

(Stuttgart) – Dr. Verena Grimm joined the BioRegio STERN Management GmbH team as a project manager in January 2017. The biotechnologist completed a tri-national degree course in Germany, Switzerland and France at the Ecole superieure de Biotechnologie de Strasbourg. After undertaking her dissertation at the University of Michigan in the United States, she received a doctorate from the Institute of Technical Biochemistry at the University of Stuttgart. She then worked for Greiner Bio-One GmbH for ten years as a product and marketing manager for multiplex analysis methods used in food safety, pharmaceutical product safety and human diagnostics. „This broad-ranging knowledge enables me to understand and reach various industries more easily,“ explains the 41-year-old. „As a project manager for BioRegio STERN Management GmbH, I will be able to put my expertise in developing, applying and marketing biotechnological methods to good use in improving links between local companies in the medical technology and biotechnology industry and help them develop opportunities for automated applications.“

About BioRegio STERN Management GmbH:
BioRegio STERN Management GmbH is a skill-sharing network, providing a help and ad-vice centre for founders of new businesses, entrepreneurs and researchers in the life sciences sector in the cities of Stuttgart, Tübingen, Esslingen and Reutlingen and the Stuttgart and Neckar-Alb regions. BioRegio STERN Management GmbH represents the interests of these market players in dealings with political circles, the media and associations and provides advice on grant applications and corporate financing. Key focal points include regenerative medicine, medical technology and the automation of biotechnology. Managing Director Dr. Klaus Eichenberg is a molecular and cell biologist and investment analyst.

Firmenkontakt
BioRegio STERN Management GmbH
Klaus Eichenberg
Friedrichstrasse 10
70174 Stuttgart
+49 (0)711-870354-0
info@bioregio-stern.de
http://www.bioregio-stern.de/en

Pressekontakt
Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Strasse 58a
70184 Stuttgart
+49 (0)711-6070719
info@zeeb.info
http://www.zeeb-kommunikation.de

Wissenschaft/Forschung

Medical Technology Report OnElMinda Ltd. – Product Pipeline Analysis, 2016

„The Report ElMinda Ltd. – Product Pipeline Analysis, 2016 Update provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz“

ElMinda Ltd. (ElMinda) is a medical technology company that offers brain disorder management solutions. The company provides tools and technologies in the areas of neuropsychological tests, functional magnetic resonance imaging, positron emission tomography, electroencephalography and magnetic encephalography. Its neuropsychological tests comprise questionnaires, pencil and paper test, computerized NP tests and continuous performance tests and behavioral or performance tests that provide an assessment of cognitive functioning. The company offers research and development programs in the areas of recovery management, pharmacologic treatment optimization, ADHD diagnosis and treatment optimization, pain management, early detection of neurodegenerative diseases, and mood disorders. It has its presence in Israel and the US. ElMinda is headquartered in Herzliya, Israel.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

View Report At http://www.marketresearchreports.biz/analysis/877740

Scope:

– The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

– The report analyzes all pipeline products in development for the company ElMinda Ltd.

– The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

– The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

– The report provides detailed description of products in development, technical specification and functions

– The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

– Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

– Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

– To formulate effective Research & Development strategies

– Develop market-entry and market expansion strategies

– Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

– Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc

– Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/877740

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

ElMinda Ltd. Company Overview 5

ElMinda Ltd. Company Snapshot 5

ElMinda Ltd. Pipeline Products and Clinical Trials Overview 6

ElMinda Ltd. Pipeline Analysis Overview 7

Key Facts 7

ElMinda Ltd. – Major Products and Services 8

ElMinda Ltd. Pipeline Products by Development Stage 9

ElMinda Ltd. Pipeline Products Overview 11

BNA Platform – ADHD 11

BNA Platform – ADHD Product Overview 11

BNA Platform – Alzheimer’s Disease 12

BNA Platform – Alzheimer’s Disease Product Overview 12

BNA Platform – Migraine 13

BNA Platform – Migraine Product Overview 13

BNA Platform – Mood Disorder 14

BNA Platform – Mood Disorder Product Overview 14

BNA Platform – Pain 15

BNA Platform – Pain Product Overview 15

BNA Platform – Parkinson’s Disease 16

BNA Platform – Parkinson’s Disease Product Overview 16

ElMinda Ltd. – Key Competitors 17

ElMinda Ltd. – Key Employees 18

ElMinda Ltd. – Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Recent Developments 20

ElMinda Ltd., Recent Developments 20

Jun 03, 2016: Study Utilizing ElMindAs BNA Awarded the International Clinical Scholar Award at American College of Sports Medicine Annual Meeting 20

Mar 02, 2016: ElMindA to Present at the Eleventh World Congress on Brain Injury: BNA As a Physiological Marker for Sports-Related Concussion 20

Apr 12, 2015: ElMindA Announces approval of BNA Analysis System by the Israeli Ministry of Health 21

Aug 04, 2014: ElMindA Announces FDA Clearance of BNA Analysis System 21

Aug 04, 2014: ElMindA Announces FDA Clearance of BNA Analysis System 22

Appendix 23

Methodology 23

About GlobalData 23

Contact Us 23

Disclaimer 23

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Wissenschaft/Forschung

„The Report ElMinda Ltd. – Product Pipeline Analysis, 2016 Update provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz“

ElMinda Ltd. (ElMinda) is a medical technology company that offers brain disorder management solutions. The company provides tools and technologies in the areas of neuropsychological tests, functional magnetic resonance imaging, positron emission tomography, electroencephalography and magnetic encephalography. Its neuropsychological tests comprise questionnaires, pencil and paper test, computerized NP tests and continuous performance tests and behavioral or performance tests that provide an assessment of cognitive functioning. The company offers research and development programs in the areas of recovery management, pharmacologic treatment optimization, ADHD diagnosis and treatment optimization, pain management, early detection of neurodegenerative diseases, and mood disorders. It has its presence in Israel and the US. ElMinda is headquartered in Herzliya, Israel.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

View Report At http://www.marketresearchreports.biz/analysis/877740

Scope:

– The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

– The report analyzes all pipeline products in development for the company ElMinda Ltd.

– The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

– The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

– The report provides detailed description of products in development, technical specification and functions

– The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

– Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

– Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

– To formulate effective Research & Development strategies

– Develop market-entry and market expansion strategies

– Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

– Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc

– Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/877740

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

ElMinda Ltd. Company Overview 5

ElMinda Ltd. Company Snapshot 5

ElMinda Ltd. Pipeline Products and Clinical Trials Overview 6

ElMinda Ltd. Pipeline Analysis Overview 7

Key Facts 7

ElMinda Ltd. – Major Products and Services 8

ElMinda Ltd. Pipeline Products by Development Stage 9

ElMinda Ltd. Pipeline Products Overview 11

BNA Platform – ADHD 11

BNA Platform – ADHD Product Overview 11

BNA Platform – Alzheimer’s Disease 12

BNA Platform – Alzheimer’s Disease Product Overview 12

BNA Platform – Migraine 13

BNA Platform – Migraine Product Overview 13

BNA Platform – Mood Disorder 14

BNA Platform – Mood Disorder Product Overview 14

BNA Platform – Pain 15

BNA Platform – Pain Product Overview 15

BNA Platform – Parkinson’s Disease 16

BNA Platform – Parkinson’s Disease Product Overview 16

ElMinda Ltd. – Key Competitors 17

ElMinda Ltd. – Key Employees 18

ElMinda Ltd. – Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Recent Developments 20

ElMinda Ltd., Recent Developments 20

Jun 03, 2016: Study Utilizing ElMindAs BNA Awarded the International Clinical Scholar Award at American College of Sports Medicine Annual Meeting 20

Mar 02, 2016: ElMindA to Present at the Eleventh World Congress on Brain Injury: BNA As a Physiological Marker for Sports-Related Concussion 20

Apr 12, 2015: ElMindA Announces approval of BNA Analysis System by the Israeli Ministry of Health 21

Aug 04, 2014: ElMindA Announces FDA Clearance of BNA Analysis System 21

Aug 04, 2014: ElMindA Announces FDA Clearance of BNA Analysis System 22

Appendix 23

Methodology 23

About GlobalData 23

Contact Us 23

Disclaimer 23

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz